As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With the fate of a $68-billion merger with Wyeth now being reviewed by the Chinese leadership, Pfizer Chief Executive Officer Jeff Kindler is on a five-day, whirlwind tour of the country, in part to launch a new wave of partnerships with scientists and scholars
You may also be interested in...
Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China
BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets
Pfizer's Core Leaders Outline Drive To Downsize In U.S., Europe While Expanding In BRIC Countries Including China
BEIJING - The core leaders of one of the globe's top pharmaceutical players - Pfizer Inc - told shareholders this week that they would push forward with a worldwide operation to reduce costs by downsizing in the West while ramping up sales forces in China and the other BRIC emerging markets
Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China
BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth